Trials / Completed
CompletedNCT00141232
Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
A Multicentre, Randomised, Double Blind Placebo Controlled Trial Evaluating Atorvastatin in Factorial With Omega-3 Fatty Acids Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 810 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The AFORRD trial is asking three important questions: What proportion of people with Type 2 Diabetes are likely to be treated satisfactorily with a fixed dose of a statin that lowers blood cholesterol levels to help reduce the risk of heart disease? To what extent do omega-3 fatty acids lower blood triglyceride levels when given with or without a statin? Are there simple techniques that can help people to take their tablets on a regular basis?
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atorvastatin and Omega-3 fatty acids |
Timeline
- Start date
- 2004-11-01
- Completion
- 2006-07-01
- First posted
- 2005-09-01
- Last updated
- 2021-02-18
Locations
59 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00141232. Inclusion in this directory is not an endorsement.